CEO Update – March 2019

THE GREATEST BREAKTHROUGH IN 30 YEARS FOR THE TREATMENT OF TREATMENT RESISTANT DEPRESSION IS SPRAVATO / ESKETAMINE!  

Is it really? Or are they just confirming what we have known for the last eight years?  Yes, finally Johnson and Johnson has successfully received FDA approval to provide the medical community with a new ketamine metabolite called Spravato or Esketamine.

I have received calls from patients, colleagues, family and friends asking me how all this would affect Ketamine Wellness Centers. I can’t tell you how excited we are to witness FDA approval of Esketamine because it essentially legitimizes what we have been doing with the generic version for almost a decade. However, there is still a lot of confusion out in the public about Esketamine including how it is dispensed, where you can get it, how much it costs, if insurance will cover it, efficacy and more.

Stay tuned! As we continue to learn more, we will keep you updated via the KWC Podcast, so you all can make the best decision about you or your loved ones and their ongoing care. We have been discussing each aspect of Esketamine in short, to-the-point podcasts, which you may listen to on our website or by subscribing to Ketamine Wellness Centers on iTunes.

Lastly, thank you to everyone who provided feedback regarding our KetWell Patient Connect Groups. Based on your responses, we have developed a Depression & Pain Support Group and a Psycho-Educational Group. Seats are limited so give us a call if you’d like to sign up!


Kevin Nicholson is the President and CEO of Ketamine Wellness Centers

CEO Update – March 2019